Skip to main content
Equibles
SMMT logo

SMMT · Summit Therapeutics Inc.

Track SMMT — free

Use SMMT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SMMT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.35 -0.65 (-4.64%) At close · Aug 14
Market Cap
$10.65B
Shares
797.75M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.35 Open$13.61 Day$12.99–13.71 52W close$12.55–26.98 Avg vol 30d3.9M Short int36.2M · 4.5% float · 8.9d Short vol52% Last earningsJul 23, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 23

Up next

Next earnings call
Nov 12, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 23, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Very Bullish Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −20%
      below
      Price vs 50-day avg −6%
      below
      RSI (14) 43
      neutral
      MACD trend Positive
      52-week position 6%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −3%
      trailing
      6-month return −17%
      trailing
      YTD return −24%
      this year
      Relative strength −31%
      vs S&P · 6-mo
      Sentiment
      smart money
      Very Bullish
      Trend (MA cross) No cross
      50d $14 › 200d $17 — 200d above 50d
      Institutional flow Accumulating
      +7% holders QoQ · +58 funds added
      Insider flow Accumulating
      Net +$103.6M over 90 days · 0% sells
      Short interest Falling
      4.54% of float · ▼ -2.9% MoM · 8.9 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Multi-yr high
      244 holders — near 3-yr high, broad support
      Squeeze score 61
      elevated · 0–100
      Fundamentals
      Weak
      EPS growth −365%
      Y/Y
      Free cash flow $-323.6M
      Balance sheet $225.3M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 74%
      annualized · 1-yr
      Max drawdown −53%
      past year
      ATR 6.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 2 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −20% Bearish
      Price vs 50-day avg
      −6% Bearish
      RSI (14)
      43 Neutral
      MACD trend
      Positive Bullish
      52-week position
      6% Bearish
      Market signals — smart money & positioning
      Bullish · 4 of 6
      Trend (MA cross) No cross
      50d $14 › 200d $17 — 200d above 50d
      Institutional flow Accumulating
      +7% holders QoQ · +58 funds added
      Insider flow Accumulating
      Net +$103.6M over 90 days · 0% sells
      Short interest Falling
      4.54% of float · ▼ -2.9% MoM · 8.9 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Multi-yr high
      244 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $13 Now $13 · 6% Range high $27
      vs 200-day avg -20% vs 50-day avg -6%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Aggregate cash and cash equivalents and short-term investments $713.4M December 31, 2025 —
      Non-GAAP G&A expenses non-GAAP $42.8M full year 2025 —
      Non-GAAP net loss non-GAAP $347.2M full year 2025 —
      GAAP → non-GAAP reconciliation
      GAAP GAAP Net Loss -1.08B
      +732.4M Stock-based compensation (Note 1)
      = Non-GAAP Net Loss -347.2M
      Non-GAAP R&D expenses non-GAAP $319.2M full year 2025 —
      patients treated in a commercial setting with ivonescimab in China 60,000 since in-licensing in January 2023 —
      patients treated with ivonescimab in clinical studies globally 4,000 since in-licensing in January 2023 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      SMMT
      Summit Therapeutics Inc.
      this stock
      		$10.65B -23.7% — — 4.5%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      244
      % held
      17.8%
      Net QoQ
      +19.5M sh
      Top holder
      BAKER BROS. ADVISORS LP
      Held Float
      View
      Held by Funds
      Fund positions
      198
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      36.2M
      Days to cover
      8.9d
      Change
      -1.1M sh
      View
      Short Volume
      Short vol %
      52%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      8.1K
      Value
      $124.8K
      As of
      Jul 6, 2026
      View
      Off-Exchange
      Off-exchange %
      40.3%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Cluster buy
      Net (90d)
      +$103.6M
      Buyers / Sellers
      3 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $0
      Net income (FY)
      $-1.1B
      EPS diluted
      $-1.44
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 5, 2026
      This year
      17
      View
      Exempt Offerings
      Offering
      $235.0M
      Filed
      Sep 26, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 23, 2026
      View
      Investor Relations
      Latest news
      Summit Therapeutics Reports Finan…
      Published
      Jul 23, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      SMMT -4.4% -3.3% -17.0% +2.5% -23.7%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -4.8% -7.8% -30.8% -1.4% -37.5%
      Key facts CIK 1599298 CUSIP 86627T108 13F (30d) 233 filings 231 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)